

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



ESSEX BIO-TECHNOLOGY LIMITED

億勝生物科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1061)

VOLUNTARY ANNOUNCEMENT

POTENTIAL IMPACT OF NOVEL CORONAVIRUS ON BUSINESS OPERATIONS;

AND

DONATION TO EXPAND HEALTHCARE RESOURCES AND SUPPORT FRONTLINE HEALTHCARE WORKERS' CONTINUING EFFORTS FOR THE NOVEL CORONAVIRUS EPIDEMIC CONTROL

This announcement is made by Essex Bio-Technology Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

POTENTIAL IMPACT OF NOVEL CORONAVIRUS ON BUSINESS OPERATIONS

In view of the outbreak of the novel coronavirus (COVID-19) that has resulted in an epidemic (the “**Epidemic**”), a number of provinces and municipalities in the People’s Republic of China (the “**PRC**”) have activated different levels of response to major public health emergencies and adopted various strict measures to curb the spread of the Epidemic (the “**Measures**”), which have significantly disrupted the clinical operations of hospitals in the PRC and have prevented non-emergency patients visiting hospitals and outpatient clinics as at the date of this announcement.

The Group is principally engaged in the manufacturing and sales of biopharmaceutical products for the treatment and healing of surface wounds and eye wounds. As the Group’s products are mainly distributed through doctors’ prescriptions in hospitals and clinics in the PRC, the Measures, if not lifted anytime soon, would interrupt the sales process of the Group’s products, which would negatively impact the Group’s turnover and results in the immediate months. However, the Group’s fundamental Research & Development (R&D) projects and on-going overseas clinical trial programmes and operations would remain on-track, with minimal disruption.

The board of directors of the Company (the “**Board**”) will continue to assess the impact of the Epidemic on the Group’s operation and financial performance and closely monitor the Group’s exposure to the risks and uncertainties in connection with the Epidemic. The Company will make further announcement(s) in accordance with the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited as and when necessary.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

DONATION TO EXPAND HEALTHCARE RESOURCES AND SUPPORT FRONTLINE HEALTHCARE WORKERS’ CONTINUING EFFORTS FOR THE NOVEL CORONAVIRUS EPIDEMIC CONTROL

In order to support prevention, control and/or relief works for the Epidemic in Wuhan, Zhuhai and other provinces and municipalities in the PRC, as at the date of this announcement, the Group has (i) made a cash donation of RMB5.0 million to a major humanitarian organisation of which RMB2.0 million was donated for the constructions of hospitals in Wuhan and RMB3.0 million was donated for the implementation of prevention and control works in Zhuhai; and (ii) donated the Group’s dermatological product, namely Beifuxin Gel, in the amount worth of RMB2.5 million to various hospitals in the PRC for alleviating frontline healthcare workers’ dermatological symptoms arising from the prolonged use of surgical masks and gloves and repeated use of sanitised products.

The donation was a reflection of the Group’s assumption of social reasonability and was made from the internal resources of the Group.

On behalf of the Board
Essex Bio-Technology Limited
Ngiam Mia Je Patrick
Chairman

Hong Kong, 17 February 2020

Executive directors of the Company as at the date of this announcement are Mr. Ngiam Mia Je Patrick, Mr. Fang Haizhou and Mr. Zhong Sheng. Independent non-executive directors of the Company as at the date of this announcement are Mr. Fung Chi Ying, Mr. Mauffrey Benoit Jean Marie and Ms. Yeow Mee Mooi.